ATE315392T1 - Zusammensetzungen zur behandlung chronischer lymphatischer leukämie - Google Patents

Zusammensetzungen zur behandlung chronischer lymphatischer leukämie

Info

Publication number
ATE315392T1
ATE315392T1 AT99937222T AT99937222T ATE315392T1 AT E315392 T1 ATE315392 T1 AT E315392T1 AT 99937222 T AT99937222 T AT 99937222T AT 99937222 T AT99937222 T AT 99937222T AT E315392 T1 ATE315392 T1 AT E315392T1
Authority
AT
Austria
Prior art keywords
compositions
treating chronic
lymphatic leukemia
chronic lymphatic
compounds
Prior art date
Application number
AT99937222T
Other languages
English (en)
Inventor
Francis A Nardella
Ruth L Sitzer
Original Assignee
Francis A Nardella
Ruth L Sitzer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Francis A Nardella, Ruth L Sitzer filed Critical Francis A Nardella
Application granted granted Critical
Publication of ATE315392T1 publication Critical patent/ATE315392T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
AT99937222T 1998-07-09 1999-07-08 Zusammensetzungen zur behandlung chronischer lymphatischer leukämie ATE315392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9246698P 1998-07-09 1998-07-09
US9487898P 1998-07-29 1998-07-29

Publications (1)

Publication Number Publication Date
ATE315392T1 true ATE315392T1 (de) 2006-02-15

Family

ID=26785713

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99937222T ATE315392T1 (de) 1998-07-09 1999-07-08 Zusammensetzungen zur behandlung chronischer lymphatischer leukämie

Country Status (12)

Country Link
US (3) US6573292B1 (de)
EP (1) EP1104297B8 (de)
JP (1) JP2002520282A (de)
AT (1) ATE315392T1 (de)
AU (1) AU767586B2 (de)
CA (1) CA2336932A1 (de)
DE (1) DE69929440T2 (de)
DK (1) DK1104297T3 (de)
ES (1) ES2255287T3 (de)
NZ (1) NZ509376A (de)
PT (1) PT1104297E (de)
WO (1) WO2000002555A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002555A1 (en) * 1998-07-09 2000-01-20 Nardella Francis A Methods and compositions for the treatment of chronic lymphocytic leukemia
US7129262B2 (en) 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US7361680B2 (en) 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
WO2004026116A2 (en) 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
EP1673373A2 (de) * 2003-10-02 2006-06-28 Salmedix, Inc. Indolderivate
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
MX2007005361A (es) * 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EA021331B1 (ru) * 2008-05-20 2015-05-29 Общество С Ограниченной Ответственностью "Инкурон" Индуцирование клеточной гибели путем ингибирования адаптивной реакции теплового шока
CA2735899A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
BRPI1004922A2 (pt) * 2009-01-15 2019-09-24 Cephalon Inc composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama
EP2605650A4 (de) 2010-08-18 2014-05-21 Del Mar Pharmaceuticals Zusammensetzungen und verfahren zur erhöhung des therapeutischen nutzens suboptimal verabreichter chemischer verbindungen einschliesslich substituierter hexitole wie dianhydrogalactitol und diacetyldianhydrogalactitol
WO2014081405A2 (en) 2011-08-17 2014-05-30 Dennis Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
CN110711188A (zh) 2012-01-20 2020-01-21 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
WO2013169600A1 (en) 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN106572992A (zh) 2014-04-06 2017-04-19 英丘伦有限责任公司 用curaxins进行组合治疗

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1071897B (de) 1957-12-19 1959-12-24
US3843480A (en) 1963-08-28 1974-10-22 D Dreher Dry dry transfer
US3948262A (en) 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3974179A (en) 1971-06-01 1976-08-10 American Home Products Corporation 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetamides and derivatives
US3843681A (en) 1971-06-01 1974-10-22 American Home Prod 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives
US3939178A (en) 1971-06-01 1976-02-17 American Home Products Corporation Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3839178A (en) * 1972-10-05 1974-10-01 Gen Electric Potentiometric oxygen sensor
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPS5777617A (en) 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
IL61721A (en) 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4542013A (en) 1981-07-08 1985-09-17 Key Pharmaceuticals, Inc. Trinitroglycerol sustained release vehicles and preparation therefrom
US4460562A (en) 1982-01-06 1984-07-17 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
US4542012A (en) 1982-07-02 1985-09-17 Minnesota Mining And Manufacturing Company Film-forming composition containing an antimicrobial agent and methods
US4608249A (en) 1982-11-02 1986-08-26 Nitto Electric Industrial Co., Ltd. Hydrophilic therapeutic material
IT1153909B (it) 1982-12-17 1987-01-21 Sogimi Srl Polimeri reattivi per la cura di affezioni cutanee
GB8317576D0 (en) 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4585877A (en) 1985-05-06 1986-04-29 American Home Products Corporation Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4748252A (en) 1986-08-15 1988-05-31 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids
US4686213A (en) * 1986-08-15 1987-08-11 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
CA2131992A1 (en) 1992-03-13 1993-09-16 James W. Young Antipyretic and analgesic methods and compositions containing optically pure r-etodolac
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5599946A (en) 1995-05-30 1997-02-04 Teva Pharmaceutical Industries Ltd. 3-(2-trialkylsilyloxy)ethyl-7-ethyl-1H-indoles and method for their preparation
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
ATE268176T1 (de) * 1995-07-19 2004-06-15 Merck & Co Inc Behandlungsverfahren für darmadenome
WO1997048391A2 (en) 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methods and compositions comprising r-ibuprofen
EP0923552A1 (de) * 1996-07-26 1999-06-23 American Home Products Corporation Pyranoindoleund carbazole als cox-2 inhibitore
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
DE69738935D1 (de) * 1996-11-05 2008-10-02 Childrens Medical Center Zusammensetzungen enthaltend Thalidomide und Dexamethason für die Behandlung von Krebs
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
WO2000002555A1 (en) * 1998-07-09 2000-01-20 Nardella Francis A Methods and compositions for the treatment of chronic lymphocytic leukemia
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
EP1307459A2 (de) 2000-08-09 2003-05-07 The Regents of the University of California Indolverbindungen und deren verwendung zur behandlung von krebs

Also Published As

Publication number Publication date
DE69929440T2 (de) 2006-08-17
EP1104297B8 (de) 2006-05-03
US6921772B2 (en) 2005-07-26
WO2000002555A1 (en) 2000-01-20
PT1104297E (pt) 2006-05-31
US20030232874A1 (en) 2003-12-18
CA2336932A1 (en) 2000-01-20
AU767586B2 (en) 2003-11-20
AU5209899A (en) 2000-02-01
EP1104297A1 (de) 2001-06-06
EP1104297B1 (de) 2006-01-11
JP2002520282A (ja) 2002-07-09
NZ509376A (en) 2003-10-31
US6573292B1 (en) 2003-06-03
EP1104297A4 (de) 2003-01-02
DK1104297T3 (da) 2006-05-29
ES2255287T3 (es) 2006-06-16
DE69929440D1 (de) 2006-04-06
US20050261356A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
ATE315392T1 (de) Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
AU9102198A (en) Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
SE9103752D0 (sv) New compounds
ATE361069T1 (de) Phytochemikalien zur behandlung von mastalgie und endometriose
NZ506329A (en) Inhibitors of phospholipase enzymes
EA200000488A1 (ru) Замена катехина на биоизостеру индазола в терапевтически активных соединениях
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
DE60023853D1 (de) Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
ATE144773T1 (de) Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
DE69719755T2 (de) Polymorphe verbindungen
DE60305484D1 (de) Verbindungen und deren verwendung als 5-ht inhibitore
TR200001906T2 (tr) Koks-Inhibitörleri olarak 2,3-ikameli indol bileşikleri.
MY136767A (en) Formulations comprising an indolinone compound
NZ507835A (en) Heterocyclic derivatives which inhibit factor XA
EA200000996A1 (ru) Конденсированные с арилом азаполициклические соединения
DE69823493D1 (de) Tetrahydropyridoverbindungen
DK1406902T3 (da) Hexahydroazepino[4,5-g]indoler og -indoliner som 5-HT-receptor-ligander
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
IT1317926B1 (it) Derivati triciclici dell'indolo ad attivita' antiangiogenica.
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
EP1671631A3 (de) Zusammensetzungen zur Behandlung von chronischer lymphatischer Leukämie

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1104297

Country of ref document: EP

REN Ceased due to non-payment of the annual fee